Frontier Capital Management Co. LLC Buys Shares of 239,811 Evolus, Inc. (NASDAQ:EOLS)

Frontier Capital Management Co. LLC acquired a new stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 239,811 shares of the company's stock, valued at approximately $2,648,000. Frontier Capital Management Co. LLC owned about 0.38% of Evolus as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in EOLS. KBC Group NV acquired a new stake in Evolus in the 4th quarter valued at $49,000. IFP Advisors Inc raised its holdings in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after acquiring an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Evolus during the fourth quarter valued at approximately $106,000. Quantbot Technologies LP bought a new position in Evolus in the fourth quarter valued at approximately $118,000. Finally, Freestone Grove Partners LP acquired a new stake in shares of Evolus in the 4th quarter valued at approximately $140,000. Institutional investors own 90.69% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on EOLS. BTIG Research initiated coverage on shares of Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 target price on the stock. Barclays upped their target price on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. Finally, Needham & Company LLC restated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research note on Thursday, May 8th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $23.75.

Evolus Stock Performance

Shares of EOLS traded up $0.02 during trading hours on Thursday, hitting $10.01. The company had a trading volume of 400,874 shares, compared to its average volume of 680,058. The firm has a market cap of $645.08 million, a price-to-earnings ratio of -11.00 and a beta of 1.11. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The business has a fifty day moving average of $11.43 and a 200-day moving average of $12.46. Evolus, Inc. has a 12 month low of $8.67 and a 12 month high of $17.82.

Insiders Place Their Bets

In other Evolus news, Director Karah Herdman Parschauer sold 12,888 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total value of $167,415.12. Following the completion of the sale, the director now owns 32,183 shares of the company's stock, valued at $418,057.17. The trade was a 28.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Rui Avelar sold 3,385 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $9.87, for a total transaction of $33,409.95. Following the transaction, the insider now directly owns 359,082 shares in the company, valued at $3,544,139.34. This represents a 0.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 70,454 shares of company stock worth $892,849 over the last three months. Insiders own 5.90% of the company's stock.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.